TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
Four sites for hematologic malignancies program open and enrolling patients
Completed pre-IND meeting with the FDA for solid tumor program; virtual investor event Monday, November 14, at 5:00 PM ET to highlight clinical trial design
Related news for (TCRX)
- MoBot alert highlights: NASDAQ: FLNC, NASDAQ: TORO, NYSE: AMBI, NASDAQ: TCRX, NYSE: UAMY (10/01/25 02:00 PM)
- MoBot’s Stock Market Highlights – 10/01/25 01:00 PM
- Don’t Miss Out: MoBot’s Latest Stock Updates 06/03/25 07:00 PM
- Breaking News: MoBot’s Latest Update as of 06/03/25 06:00 PM
- Breaking News: MoBot’s Latest Update as of 06/03/25 05:00 PM
